I N T R O D U C T I O N
Uraemic cardiomyopathy is a common complication in chronic kidney disease (CKD) and a leading cause of death in these patients [1] . Usually caused by cardiac fibrosis and hypertrophy, the cellular bases of this pathological process include increases in both cardiomyocyte size and collagen synthesis. These changes progressively lead to apoptosis or necrosis of cardiomyocytes, which are replaced by fibroblasts and extracellular collagen [2] .
Treatment with vitamin D receptor activators (VDRAs) attenuates the development and severity of both renal and cardiac fibrosis in uraemia. In a rat model of chronic renal failure (CRF), administration of VDRAs attenuates the hypertrophic growth of cardiomyocytes and thickening of the left ventricle (LV) wall together with a reduction of the heart:body weight ratio and a decrease in the percentage of collagen fibres [3] . Calcitriol, the endogenous and most frequently administered VDRA, reduces cardiac fibrosis by decreasing the expression of transforming growth factor (TGF)-b1 and accumulation of collagen types I and III in the heart of subtotally nephrectomized rats [4] . preventing myocardial fibrosis, acting on the decrease in VDR levels [5] but also on collagen types I and III [6] among others. In addition, paricalcitol reduces fibrotic kidney injury by decreasing the expression of fibrogenic TGF-b1, connective tissue growth factor (CTGF) and collagen types I and III, as well as by increasing matrix metalloproteinase 1 (MMP-1) expression [7] .
Several microRNAs (miRNAs), small 22-24 nucleotide noncoding RNA molecules, negatively regulate the expression of genes controlling heart function and structure [8, 9] . Regarding fibrosis, miR-29 targets genes encoding collagen types I and IV and MMP-2, among others [10, 11] . Downregulation of miR-29 by TGF-b1/Smad3 is part of the mechanism by which this signalling pathway induces renal fibrosis [12] . In addition, the loss of miR-30 and miR-133 in the course of LV hypertrophy intensifies pro-fibrotic signalling, in part through increases in CTGF levels [13] . Importantly, VDRAs directly regulate the transcription of miRNAs, turning them into potential therapeutic agents [14] . In addition, miRNAs have emerged as accurate diagnostic and prognostic biomarkers in several cardiac disorders [15, 16] .
As both miRNAs and VDRAs regulate cardiac fibrosis, this study examined whether some miRNAs could be mediators of the anti-fibrotic effects of VDRAs, the accuracy of these miRNAs as biomarkers of cardiac fibrosis in uraemia and the potential direct transcriptional control of miRNA expression by VDRAs.
M A T E R I A L S A N D M E T H O D S

Experimental animals
A total of 29 male Wistar rats (350-400 g weight) were used for the experiments. Animals were fed a standard rodent chow containing 0.6% calcium, 0.6% phosphorus and 1000 IU vitamin D3/kg (Panlab) and housed in wire cages in a temperaturecontrolled environment with a 12-h light/dark cycle, with water and food ad libitum. CRF was induced in 22 rats by 7/8 nephrectomy as previously described [17] . One week after surgery, nephrectomized rats were divided into three groups: group 1 (CRF þ vehicle, n ¼ 7) received vehicle (corn oil 0.8 mL/kg body weight/day), group 2 (CRF þ calcitriol, n ¼ 8) received calcitriol (10 ng/kg body weight/day) and group 3 (CRF þ paricalcitol, n ¼ 7) received paricalcitol (30 ng/kg body weight/day). Calcitriol and paricalcitol doses were established from the ratio (1:3) used clinically [18] and experimentally to achieve a similar degree of parathyroid hormone (PTH) suppression [3] . All compounds were dissolved in ethanol and diluted with corn oil to a final volume of 0.8 mL/kg body weight/day and administered intraperitoneally 5 days/week over a period of 4 weeks. A group of rats with normal renal function served as the reference group (sham þ vehicle, n ¼ 7).
After 4 weeks of treatment, rats were first placed in metabolic cages for a 24-h urine collection and then sacrificed using CO 2 anaesthesia. Serum and hearts were obtained for analyses. Hearts were washed twice with saline, blotted dry, weighed and the LV was frozen at À80 C until analysis. Two LV pieces were used for RNA and protein extraction and the remnant fragment was fixed, embedded in paraffin and sliced for histological studies.
This protocol was approved by the Ethics Committee in Research of the University of Oviedo.
Biochemical markers
Serum creatinine, calcium, phosphorus and creatinine clearance were measured using a multichannel auto analyser (Hitachi 717; Boehringer Mannheim). Serum intact PTH was measured by immunoradiometric assay (Rat iPTH kit; Immutopics), and serum intact fibroblast growth factor 23 (FGF23) with a sandwich ELISA kit (Kainos Laboratories), following the manufacturer's protocol.
Sirius red staining for fibrosis determination
Myocardial total collagen content was determined using Sirius red staining [4] in deparaffined sections of the LV and quantified by using an optical microscope (model DMRXA2, Leica Microsystems) coupled to a digital video camera (model Dc-100, Leica Microsystems). The stained collagen area was measured using semi-automatic image analysis software (Leica QWIN standard version 2.3, Leica Microsystems). Measurements were performed by a technician blinded to treatment. Results were expressed as the percentage of red area of the total myocardial area.
Immunohistochemistry
Tissue COL1A1, MMP-2 and CTGF localization were assessed by immunohistochemistry in 5-mm sections, incubated overnight at 4 C with primary antibodies against COL1A1 (1:2000 dilution; Merck Millipore), MMP-2 (1:100; Santa Cruz Biotechnology) and CTGF (1:500; Sigma) and then washed and incubated with biotinylated secondary antibody following the manufacturer's instructions (Dako REAL EnVision). Like with Sirius red staining, semi-automatic image analysis software (Leica QWIN standard version 2.3, Leica Microsystems) was used. A negative control without primary antibody was used to set the level of the lowest detectable staining intensity.
Total RNA isolation, cDNA synthesis and quantitative polymerase chain reaction (qPCR)
Total RNA was isolated in Tri Reagent (Sigma-Aldrich) from a fragment of the LV homogenized in an Ultraturrax (OmniHT) or from 400 lL of serum from rats, following the manufacturer's instructions. Total RNA concentration and purity were quantified by UV-Vis spectrophotometry (NanoDrop). Gene expression was measured by retrotranscription with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) followed by quantitative PCR (qPCR) using a Stratagene Mx3005P (Agilent Technologies). TaqMan qPCR amplification was performed with genespecific primers (Gene Expression Assays; Applied Biosystems) for genes implicated in fibrosis: (COL1A1), MMP-2 and CTGF.
Mature miRNA expression levels were analysed from total RNA using Taqman miRNA assays (Applied Biosystems) for rat miR-29b, miR-30c and miR-133b, according to the
manufacturer's instructions. qPCR was performed on the resulting complementary DNA using the appropriate TaqMan miRNA Gene Expression Assay. Endogenous rat small nuclear RNA U6 for tissue sample and exogenously added 4.5S for serum samples were used as references [19] . The relative quantitative evaluation of target genes was performed by comparing threshold cycles using the DDCt method [20] .
Western blot analysis
Total protein extracts from homogenized LV were collected, quantified by the Bradford assay (Bio-Rad) and equal amounts of protein were separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Hybond). Western blot analyses were performed as per the manufacturer's protocol with specific antibodies: COL1A1 (dilution 1:1000; Abcam), MMP-2 (dilution 1:500; Santa Cruz Biotechnology), CTGF (dilution 1:1000; Sigma) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (dilution 1:30000; Santa Cruz Biotechnology). Secondary antibody binding was detected with an ECL Western Blotting Detection Kit (Amersham BioSciences) and the ChemiDoc Gel Imaging System Model XRSþ (Bio-Rad) and quantified using Quantity One 1-D Analysis Software v4 (Bio-Rad).
Statistical analysis
Statistical comparisons between groups were carried out using one-way analysis of variance and Student's t-test. Bivariate correlation analyses were performed. The results were expressed as mean 6 SD. Differences were considered significant for P-values <0.05. All statistical analyses were performed using SPSS 17.0 for Windows.
R E S U L T S
VDRAs attenuated the cardiac fibrosis induced by CRF in rats
The three groups of CRF rats receiving vehicle, calcitriol or paricalcitol for 4 weeks had a similar degree of renal failure, as indicated by creatinine clearance values ( Table 1) . As expected, both VDRA treatments significantly increased calcium and FGF23 serum levels and decreased PTH ( Table 1 ). The persistence of the uraemic state for 4 weeks induced a significant increase in collagen fibres in the heart, measured as Sirius red staining of the LV wall ( Figure 1 ). Despite higher FGF23, VDRA treatment attenuated the increase in the percentage of collagen fibres, which achieved statistical significance only in the paricalcitol group. In fact, the collagen fibre content in the paricalcitol group was similar to the levels in the sham-operated rats receiving vehicle.
VDRA treatment attenuated CRF induction of cardiac pro-fibrotic genes in CRF rats
The expression of cardiac COL1A1 ( Figure 2 ) and MMP-2 ( Figure 3 ) increased significantly in the CRF rats receiving vehicle. The rats receiving calcitriol did not have a significant change in either cardiac COL1A1 or MMP-2 levels compared with CRF þ vehicle rats. In contrast, and despite higher FGF23, paricalcitol treatment prevented increases in the mRNA and protein levels for both molecules, which remained at levels similar to those in the sham þ vehicle group (Figures 2 and 3) .
Four weeks of uraemia also increased the mRNA and protein levels of CTGF, an inducer of cardiac fibrosis, in the LV wall compared with the levels in sham þ vehicle rats (Figure 4) . Calcitriol treatment only slightly attenuated the increases in CTGF, whereas paricalcitol fully prevented the increases in Table 1 . Biochemical parameters
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VDRAs attenuate uraemia-induced alterations in cardiac miRNA levels
Cardiac levels of miR-29b, miR-30c and miR-133b, which target the pro-fibrotic genes COL1A1, MMP-2 and CTGF, were modified not only by the uraemic state but also by VDRA treatment. Only miR-29b and miR-30c levels showed a significant reduction in the LV wall of uraemic rats (CRF þ vehicle rats compared with the sham þ vehicle group; Figure 5A and B). While calcitriol treatment partially prevented this decrease, paricalcitol fully prevented these reductions, maintaining miRNAs levels similar to those in sham þ vehicle rats. Interestingly, miR-133b was inversely regulated by uraemia compared with miR-29b and miR-30c, although the increase did not reach statistical significance ( Figure 5C ).
VDRAs attenuate uraemia-induced increases in serum levels of miRNAs
Serum levels of miR-29b, miR-30c and miR-133b were measured to examine their potential as biomarkers of cardiac fibrosis in uraemia and all of them were significantly increased. These increases in circulating miRNAs were prevented by VDRA treatment, with paricalcitol showing the greatest effectiveness ( Figure 6 ). The pattern of serum miRNA levels were similar, showing the degree of cardiac fibrosis, as determined by Sirius red staining (Figure 1 ). In fact, there was a significant positive correlation between serum levels of the three miRNAs and the degree of cardiac fibrosis (Figure 7) .
Identification of putative vitamin D response elements (VDREs) in the miRNA genes
VDRAs can directly regulate miRNA expression through the binding of VDR/VDRA to VDREs in the promoter of miRNA genes to regulate their transcription [14] . The presence of putative VDREs was examined in the 10-kb region upstream of each transcriptional start site of the three rat miRNA genes, obtained from the University of Santa Cruz genome browser (http://www.genome. ucsc.edu; RefSeq numbers NR_031837 for Mir29b1, NR_031839 for Mir30c1 and NR_032117 for Mir133b). The open-access database of transcription factor binding profiles JASPAR 2016 (http:// jaspar.genereg.net) [21] identified five, one and three putative 15-bp classical VDREs in the Mir29b1, Mir30c1 and Mir133b genes, respectively ( Figure 8 ).
D I S C U S S I O N
This study demonstrates that the maintenance of cardiac levels of miR-29b and miR-30c expression by treatment with VDRAs could contribute to the anti-fibrotic effect of these activators on uraemia-induced cardiac fibrosis. Furthermore, this study presents the increases in serum levels of miR-29b, miR-30c and miR-133b as potential biomarkers of the degree of cardiac fibrosis in uraemia (Figure 9 ). The three miRNAs selected for the study are recognized regulators of cardiac fibrosis [13, 22] , with miR-29b and miR30c abundant in cardiac fibroblasts and miR-133b in cardiomyocytes. Regarding miR-29b, our study showed that untreated uraemic rats had higher levels of its targets COL1A1 and MMP-2 in the LV wall, concurring with the lowest levels of miR-29b, supporting its action in reducing the expression of several collagens, including COL1A1, and MMP-2 secretion [23] . While MMPs usually degrade collagen and prevent its accumulation, MMP-2 stimulates COL1A1 synthesis in cardiac fibroblasts through phosphorylation of focal adhesion kinase [24] , thus rendering MMP-2 a pro-fibrotic agent. miR-30 and miR-133 are also negative regulators of fibrosis. Both miRNAs directly downregulate CTGF, a key molecule in the synthesis of extracellular matrix proteins in fibrosis [13] . In the heart, both cardiomyocytes and fibroblasts produce and secrete CTGF. Because miR-133b is expressed mainly in cardiomyocytes, whereas miR-30c is expressed in both cell types, CTGF protein levels may be regulated by miRNAs in a cellspecific manner. Cell specificity could partially explain why there was no clear association between cardiac expression of -30c ) and cardiac fibrosis, a feature more related to fibroblasts [2] .
An additional contribution of our study is that part of the anti-fibrotic effects of VDRAs in the heart could be attributed to the control of anti-fibrotic miRNAs and, to our knowledge, there is no prior evidence linking the regulation of miRNAs by VDRAs with cardiac fibrosis. The VDRAs used in this study efficiently prevented LV fibrosis, especially paricalcitol, which maintained levels of miR-29b and miR-30c similar to those in the hearts of sham rats. Previously we reported that VDRAs, mainly paricalcitol, prevented uraemia-induced cardiac fibrosis through inhibition of TGF-b1, and even despite elevations in FGF23 levels [3] . This could be explained because the adverse cardiac effect of FGF23 is mainly an increase in left ventricular mass due to the hypertrophy of cardiomyocytes [25] and thus the beneficial effects of VDRAs could be similar to the inhibition of several pro-fibrotic genes [7] . However, a very recent work has demonstrated that elevated FGF23 also promotes myocardial fibrosis in mice [26] , continuing the controversy about the mechanisms by which VDRAs have beneficial effects in heart. Regarding miRNAs, in a model of cardiac fibrosis induced by angiotensin II, it was also described that miR-29b inhibits TGFb/Smad3 signalling, inhibiting cardiac fibrosis in vivo and in vitro [27] . Therefore, the actions of miR-29b in this pathway may account in part for the protective effect found in the uraemic rat model. Although a role for VDR-Smad3 interactions in the control of TGF-b-driven cardiac fibrosis could not be completely ruled out [28] , our work provides solid bases in support of the contribution of VDRA regulation of miRNA expression to their anti-fibrotic actions in the uraemic heart.
VDRAs could globally increase miRNAs expression, as most miRNA-profiling studies identified more miRNAs upregulated by vitamin D metabolites than downregulated [14] . Several mechanisms may cause such a global effect: one is regulation of the miRNA processing machinery by VDRAs, as specifically demonstrated for calcitriol and the endoribonuclease Dicer [29] . There is also evidence of direct transcriptional control of specific miRNA expression by VDRAs through binding of the VDR/ RXR heterodimer to VDREs in the promoters of miRNA genes [30] . Supporting this mechanism, our study has identified several putative binding sites for VDR and VDR/RXR in the proximal promoters of the three miRNAs regulating fibrosis that could be responsible for their regulation by VDRAs. This regulation can be distinct in different cell types. In fact, differences in VDR comodulators explain in part the selectivity of paricalcitol actions compared with calcitriol [31] .
Because of their remarkable stability in blood, the simplicity for their isolation and detection techniques and their distinct tissue and disease-specific expression, as demonstrated in several human cancer types [32] [33] [34] , abnormal pregnancies [35] and cardiopathies [36] , miRNAs could have great potential as diagnostic biomarkers in uraemic cardiomyopathy [37] . In fact, changes in circulating muscle-specific miRNAs, especially miR-133b, can reflect early myocardial injury after heart transplantation [38] or an association with acute myocardial infarction [39] . Herein we have presented evidence of the potential of three specific miRNAs as accurate circulating biomarkers of cardiac fibrosis. This approach is particularly important since myocardial fibrosis is difficult to diagnose noninvasively [40] . Indeed, the use of circulating levels of miRNAs is being explored in hypertrophic cardiomyopathy [41] . Specifically, plasma miR29b has been reported to be elevated in heart failure [42] and Regarding miR-30, its circulating levels are considered an important diagnostic marker for left ventricular hypertrophy [43] , a condition strongly associated with myocardial fibrosis. Similar to our findings, Pan et al. [43] showed that miR-30 is decreased in the heart of uraemic rats, but its serum levels are increased. It is possible that the opposite change in systemic versus cardiac miR-30 expression, also observed for miR-29b in our study, could reflect a release of these miRNAs from the cardiac tissue to the circulation [44] , induced in this case by uraemia. This uraemia-induced release could partially account for the reduction in miRNAs in the LV of untreated uraemic rats. However, a decrease in circulating levels of miR-30c, among others, has been shown in heart failure [45] , thus responding to a different mechanism depending upon the cause of cardiac injury. In the same way, that hypothesis fails to explain the increases in circulating miR-133b, similar to those of miR-29b and miR-30c, despite its different expression in the heart. We have to consider that in addition to tissue-derived miRNAs, blood cells are major contributors to circulating miRNAs [46] . This highlights the importance of determining the specificity of the miRNAs detected in blood when considering them as biomarkers of a process affecting a particular tissue. It is also possible that their Proposed interactions between miRNAs and VDRAs in uraemia-induced myocardial fibrosis. In uraemia (CRF), the LV wall shows increased levels of the pro-fibrotic genes COL1A1, MMP-2 and CTGF caused in part by decreases in miR-29b and miR-30c that negatively regulate their expression, resulting in increased myocardial fibrosis and serum levels of miR-29b, miR-30c and miR-133b. Treatment with VDRAs, especially with paricalcitol, attenuated all of these changes, maintaining cardiac levels of COL1A1, MMP-2, CTGF as well as cardiac and serum levels of miR-29b, miR-30c and miR-133b similar to those in a healthy heart. plasma levels are not reflecting an adverse regulation of their expression by uraemia exclusively in the heart, since these miRNAs are involved in the regulation of fibrosis in other tissues. In any case, this is an experimental study and therefore confirmation of these results in the plasma of CRF patients receiving VDRA treatment is mandatory.
Our findings also highlight the importance of potential therapeutic interventions with these miRNAs [47] . The addition of exogenous miR-29 decreases fibrosis in the liver [48, 49] , lung [50] , kidney [12] and, significantly, in the heart [51] . In fact, in established hypertension, the restoration of miR-29b levels was sufficient to prevent the progression of cardiac fibrosis and improve cardiac dysfunction [27] .
In summary, we have shown that calcitriol, and mainly paricalcitol, reduces cardiac fibrosis induced by uraemia acting on COL1A1, MMP-2 and CTGF expression in part through the maintenance of cardiac miR-29b and miR-30c expression and prevention of an increase in their circulating levels. In addition, miR-29b, miR-30c and miR-133b could be not only accurate serum biomarkers of cardiac fibrosis but, more importantly, potential new therapeutic targets, as they constitute strong regulators of the fibrotic process. 
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